Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

98.33
+1.611.66%
Volume:169.98K
Turnover:16.85M
Market Cap:6.38B
PE:-6.98
High:100.20
Open:98.50
Low:95.00
Close:96.72
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:0.43
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-612.63
PE(LYR):-209.21

Loading ...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), GeneDx Holdings (WGS) and Agios Pharma (AGIO)

TIPRANKS
·
Apr 21

Mirum director Saira Ramasastry disposes of USD 193,800 in common shares

Reuters
·
Apr 17

BRIEF-Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 14

Mirum grants inducement awards to 12 hires under 2020 plan

Reuters
·
Apr 14

Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Apr 10

Egetis appoints Tiago Nunes chief medical officer, replacing retiring Kristina Sjöblom Nygren

Reuters
·
Apr 09

Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Apr 09

Mirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?

Simply Wall St.
·
Apr 05

Assessing Mirum Pharmaceuticals (MIRM) Valuation After Record Revenues First GAAP Profitability And Key Trial Milestones

Simply Wall St.
·
Apr 04

Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi Year Surge?

Simply Wall St.
·
Mar 31

Mirum Pharmaceuticals Price Target Maintained With a $130.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 23

Mirum Pharmaceuticals Director Saira Ramasastry Disposes of USD 181,520 in Common Shares

Reuters
·
Mar 18

Mirum Pharmaceuticals Completes Enrollment In Phase 3 Expand Study Of Livmarli® (Maralixibat) In Additional Rare Cholestatic Liver Diseases

Reuters
·
Mar 16

Mirum Pharmaceuticals Inc - Topline Data From Expand Study Expected in Q4 2026

THOMSON REUTERS
·
Mar 16

Santhera appoints Marc Clausse as Chief Commercial Officer effective June 1, 2026

Reuters
·
Mar 10

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM) and Talkspace (TALK)

TIPRANKS
·
Mar 10

Mirum completes enrollment in AZURE-1 study, screening in AZURE-4 study

TIPRANKS
·
Mar 05

BRIEF-Mirum Pharmaceuticals Provides Azure Clinical Program Update For Brelovitug In Chronic Hepatitis Delta Virus

Reuters
·
Mar 05

Mirum Completes AZURE-1 Enrollment and AZURE-4 Screening for Brelovitug in Chronic HDV

Reuters
·
Mar 05

Mirum Pharmaceuticals Inc - Topline Azure-1 and Azure-4 Data Expected in 2H 2026

THOMSON REUTERS
·
Mar 05